{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000044","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.146563+00:00","generated_at":"2026-05-26T05:55:10.467450+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Summit Therapeutics reports FY2024 net loss $221.3M; HARMONi enrollment complete, data mid-2025","bullets":["Cash & short-term investments $412.3M at Dec 31, 2024, up from $186.2M at Dec 31, 2023.","GAAP net loss $221.3M ($0.31/share) vs $614.9M ($0.99/share) prior year.","GAAP R&D expense $150.8M vs $59.4M prior year, driven by ivonescimab development.","HARMONi Phase III trial enrollment complete; top-line data expected mid-2025; FDA Fast Track granted.","Pfizer collaboration to evaluate ivonescimab with vedotin ADCs in solid tumors; studies start mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000044","json":"https://secwatch.observer/filing/0001599298-25-000044.json","markdown":"https://secwatch.observer/filing/0001599298-25-000044.md","text":"https://secwatch.observer/filing/0001599298-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000044/0001599298-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000044/smmt-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:55:10.467450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}